Belgian biopharmaceutical firm Ablynx has appointed Dr Andreas Menrad as chief scientific officer.
Dr Menrad has more than 20 years’ experience in the pharmaceutical and biotech industry, with significant expertise in drug discovery and the progression of leading drug candidates into pre-clinical development. He will be responsible for the ongoing development of Ablynx’s Nanobody platform and identify and prioritise new therapeutic programmes that will be taken forward either on its own or with partners.
Prior to joining Ablynx, Dr Menrad was at Genzyme for five years, where since 2011 he held the position of general manager and vice president of Antibody Therapeutics. Previously he has also held senior research positions with Schering.
Ablynx strengthens management team
Appoints Dr Andreas Menrad as chief scientific officer
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Drug Delivery
Future drug success is all in the delivery
Today, the mode of delivery can play a huge part in drug choice and success, thus new delivery technologies are proving to be a lucrative draw for drug formulators in all therapy categories. Susan Birks reports on market progress and predicted growth in the various categories
